Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 40 of 40 drug-target rows in SSL view, for TSG = STAG1.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
olaparib STAG1 PARP2 1
olaparib STAG1 PARP1 1
olaparib STAG1 PARP3 2
18f-fluoromisonidazole, cediranib maleate, laboratory biomarker analysis, olaparib, positron emission tomography STAG1 PARP3 1
afatinib, dasatinib, palbociclib, everolimus, olaparib STAG1 PARP3 1
azd1775, olaparib STAG1 PARP3 1
bevacizumab, cediranib, cediranib maleate, olaparib STAG1 PARP3 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib STAG1 PARP3 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, pembrolizumab STAG1 PARP3 1
biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, placebo administration STAG1 PARP3 1
capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab STAG1 PARP3 1
ceralasertib, olaparib, durvalumab STAG1 PARP3 1
cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab STAG1 PARP3 1
durvalumab, olaparib STAG1 PARP3 1
durvalumab, olaparib, cediranib STAG1 PARP3 1
ep0057, olaparib STAG1 PARP3 1
fluorouracil, irinotecan sucrosofate, laboratory biomarker analysis, leucovorin calcium, rucaparib STAG1 PARP3 1
nab-paclitaxel, gemcitabine, cisplatin, irinotecan, capecitabine, pembrolizumab, olaparib STAG1 PARP3 1
olaparib, olaparib, placebo, placebo STAG1 PARP3 1
olaparib, ramucirumab STAG1 PARP3 1
olaparib, temozolomide (tmz), imrt (intensity modulated radiation therapy) STAG1 PARP3 1
olaparib, temozolomide, gene expression analysis, protein expression analysis, laboratory biomarker analysis, pharmacological study, diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, therapeutic conventional surgery STAG1 PARP3 1
olaparib, temozolomide, irinotecan STAG1 PARP3 1
pamiparib, olaparib, radiation therapy, temozolomide STAG1 PARP3 1
pembrolizumab, olaparib STAG1 PARP3 1
pembrolizumab, olaparib, temozolomide STAG1 PARP3 1
rucaparib STAG1 PARP3 1
rucaparib, ramucirumab, nivolumab STAG1 PARP3 1
niraparib STAG1 PARP2 7
niraparib STAG1 PARP1 7
niraparib tosylate STAG1 PARP2 7
niraparib tosylate STAG1 PARP1 7
rucaparib STAG1 PARP2 7
rucaparib STAG1 PARP1 7
rucaparib camsylate STAG1 PARP2 7
rucaparib camsylate STAG1 PARP1 7
talazoparib STAG1 PARP2 7
talazoparib STAG1 PARP1 7
talazoparib tosylate STAG1 PARP2 7
talazoparib tosylate STAG1 PARP1 7
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.